Sign In
Buy XPHYF
$0.284
+0 (+0%)
At Close: Apr 17, 2023
Xphyto Therapeutics Corp said it has made two key appointments to continue its focus on research, development and commercialization of its biosensor and diagnostic products, including for the detectio
XPhyto progressing its scientific approach to cannabis-based medicine and helping in the coronavirus fight
11:39pm, Wednesday, 15'th Dec 2021
German subsidiary, Vektor Pharma has developed an oral disintegrating film (ODF) for drug delivery Developed low-cost oral screening test to concurrently detect COVID-19 and non-COVID-19 coronaviruse
XPhyto epilepsy clinical trial planned in 2022 with its proprietary fast-dissolving CBD oral strips
08:21am, Wednesday, 15'th Dec 2021
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) provided an update on the development of its fast-dissolving CBD oral strips, noting that its European human CBD bioavailability study will start in
XPhyto Therapeutics completes strategic acquisition of 3a-diagnostics GmbH
08:19am, Monday, 06'th Dec 2021
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) revealed that its acquisition of biotechnology company 3a-diagnostics GmbH (3a), first announced on July 20, 2021, is now complete. "The strategic acq
XPhyto Therapeutics closes its private placements for gross proceeds of C$7M
12:16pm, Monday, 29'th Nov 2021
XPhyto Therapeutics Corp said it has completed its non-brokered private placement as well as its previously-announced non-brokered convertible debenture unit offering, raising total gross proceeds of
XPhyto Therapeutics appoints Joseph Meagher as its chief financial officer
07:44am, Monday, 22'nd Nov 2021
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) said it has appointed Joseph Meagher as chief financial officer of the company. Meagher, a Chartered Professional Accountant and a Chartered Director
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF)has announced the appointment of Professor Dr Thomas Beckert as the managing director of its 100% owned subsidiary XP Diagnostics GmbH and has also l
XPhyto Reports Development Update for its Drug Delivery Business
03:05am, Tuesday, 12'th Oct 2021
Rotigotine transdermal skin patch optimization and pivotal study planning underway Rotigotine patch manufacturing, sales and marketing in preparation Cannabinoid oral dissolvable film (ODF) programs a
Xphyto Announces Engagement of Consultants for Marketing and Promotional Activities
07:00pm, Friday, 08'th Oct 2021
VANCOUVER, BC / ACCESSWIRE / October 8, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the"Company") announces it has entered into extensions to investor relations cons
COVID Tests, THC Patches, Psychedelics: Xphyto Therapeutics Does it All
08:48am, Monday, 04'th Oct 2021
Image by Shameer Pk from Pixabay From 25-minute COVID-19 lab tests to psychedelic medicine that is poised to address mental health conditions like PTSD, XPhyto Therapeutics (OTCQB: XPHYF) has a knack
XPhyto Reports Successful Market Launch and Growing Demand for its 25-minute COVID-19 PCR Test COVID-ID Lab
03:05am, Wednesday, 08'th Sep 2021
VANCOUVER, BC and FRANKFURT, GERMANY / ACCESSWIRE / September 8, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce the successful m
XPhyto Launches First Commercial Biosensor for Oral Disease
03:05am, Monday, 30'th Aug 2021
Biosensor test dissolves on the tongue and turns bitter indicating the presence of oral inflammation after five minutes Easy and simple at-home self-checks improve oral health and indicate inflammatio
XPhyto's Acquisition Target, 3a-Diagnostics, Reports Breakthrough Identification of COVID-19 Biosensor Candidates
03:05am, Wednesday, 28'th Jul 2021
First saliva activated biosensor molecules identified to diagnose COVID-19 infection using XPhyto's oral dissolvable delivery platform Biosensor candidates are ready for optimization and performance
XPhyto in transformative acquisition with 3a-diagnostics to enter hi-tech biosensor market and expand diagnostic product portfolio
08:03am, Tuesday, 20'th Jul 2021
XPhyto Therapeutics Corp. (CSE:XPHY ) (OTCQB:XPHYF) (FRA:4XT) said it has signed a definitive agreement for the acquisition of Germany-based 3a-diagnostics GmbH, which will becoime its exclusive diag
The acquisition creates significant commercial development and manufacturing opportunities for XPhyto as well as cost synergies and improved margins on its diagnostic products. The acquisition secures
